Skip to content

Dynamic changes of peripheral blood monocyte subsets and neurological recovery in stroke patients

Predictive Value of Dynamic Changes in Peripheral Monocyte Subsets for Neurological Prognosis in Patients with Stroke: A Prospective Longitudinal Observation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115450
Enrollment
Unknown
Registered
2025-12-26
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke?(AIS)

Interventions

AIS Group:NA
(VRF) Control Group:NA

Sponsors

Rugao People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: AIS Group 1. Age: Patients aged between 40 and 80 years. 2. Diagnosis: Clinically diagnosed with Acute Ischemic Stroke (AIS). 3. Imaging Confirmation: Acute cerebral infarction lesions confirmed by CT or MRI imaging. 4. Timing: Able to undergo the first blood sample collection (T1) within 24 hours of symptom onset. 5. Informed Consent: The patient or their legal guardian has signed the informed consent form. Vascular Risk Factors (VRF) Control Group 1. Matching: Generally matched with the AIS group in terms of age and gender. 2. Key Criteria: Must have at least two vascular risk factors (e.g., hypertension with diabetes mellitus, or hypertension with hyperlipidemia), but no history of stroke or Transient Ischemic Attack (TIA).

Exclusion criteria

Exclusion criteria: 1. Imaging-confirmed Intracranial Hemorrhage: Diagnosis of Intracerebral Hemorrhage (ICH) or Subarachnoid Hemorrhage (SAH) by imaging. 2. Active Infection or Fever: Known active infection upon admission (e.g., pneumonia, urinary tract infection) or body temperature > 38°C. 3. Chronic Inflammatory or Autoimmune Diseases: Known systemic autoimmune diseases or chronic inflammatory conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus). 4. Recent Major Trauma or Surgery: Major surgery or severe trauma within the past 3 months. 5. Immunosuppressant Use: Long-term use of immunosuppressive agents (e.g., glucocorticoids, chemotherapeutic drugs). 6. Hematologic Malignancies: Presence of any hematological malignancy.

Design outcomes

Primary

MeasureTime frame
Neurological functional prognosis (Modified Rankin Scale, mRS);NIHSS score;

Secondary

MeasureTime frame
Proportions of peripheral monocyte subsets (classical, intermediate, non-classical);CCR2 MFI on monocytes;HLA-DR MFI on monocytes;CX3CR1 MFI on monocytes;Serum IL-6 levels;Serum CCL2 levels;Serum IL-10 levels;

Countries

China

Contacts

Public ContactLu Jing

Rugao People's Hospital

lj2023njmu@163.com+86 187 5284 8900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026